Novel anticoagulants and antiplatelet agents; a guide for the urologist

BJU InternationalVolume 116, Issue 5 p. 687-696 Review Novel anticoagulants and antiplatelet agents; a guide for the urologist Gidon Ellis, Gidon Ellis Department of Urology, Whittington Hospital, London, UKSearch for more papers by this authorAlan John Camm, Alan John Camm Department of Clinical Cardiology, St George's Healthcare NHS Trust, London, UKSearch for more papers by this authorSoumendra N. Datta, Corresponding Author Soumendra N. Datta Department of Urology, Colchester Hospital University Foundation Trust, Colchester, UK Correspondence: Soumendra N. Datta, Department of Urology, Colchester Hospital University Foundation Trust, Colchester, UK. e-mail: [email protected]Search for more papers by this author Gidon Ellis, Gidon Ellis Department of Urology, Whittington Hospital, London, UKSearch for more papers by this authorAlan John Camm, Alan John Camm Department of Clinical Cardiology, St George's Healthcare NHS Trust, London, UKSearch for more papers by this authorSoumendra N. Datta, Corresponding Author Soumendra N. Datta Department of Urology, Colchester Hospital University Foundation Trust, Colchester, UK Correspondence: Soumendra N. Datta, Department of Urology, Colchester Hospital University Foundation Trust, Colchester, UK. e-mail: [email protected]Search for more papers by this author First published: 23 March 2015 https://doi.org/10.1111/bju.13131Citations: 20Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Novel oral anti-coagulants (NOACs) are increasingly being used in clinical practice and are set to almost entirely replace the vitamin K antagonists, such as warfarin, in the near future. Similarly, new antiplatelet agents are now regularly used in place of older agents, such as aspirin and clopidogrel. In an ageing population, with an increasing burden of complex comorbidities, urologists will frequently encounter patients who will be using such agents. Some background knowledge, and an understanding, of these drugs and the issues that surround their usage, is essential. The present article will provide readers with an understanding of these new drugs, including their mechanisms of action, the up-to-date evidence justifying their recent introduction into clinical practice and the appropriate interval for stopping them before surgery. It will also consider the risks of perioperative bleeding for patients taking these drugs and the risks of venous thromboembolism in those in whom they are stopped. Strategies to manage anticoagulant-associated bleeding are discussed. Citing Literature Volume116, Issue5November 2015Pages 687-696 RelatedInformation